August 29, 2010Open Access
View Full PaperTicagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
Key Points
- This research aims to compare the effects of ticagrelor and clopidogrel on ischaemic events in patients with acute coronary syndromes and diabetes.
- Analyzed patient outcomes from the PLATO trial focusing on diabetic ACS patients
Structured PICO
Does ticagrelor reduce ischaemic events compared to clopidogrel in patients with acute coronary syndromes and diabetes?
P
Population
Patients with acute coronary syndromes and diabetes
I
Intervention
Ticagrelor
C
Comparator
Clopidogrel
O
Outcome
Ischaemic eventscomposite
Ticagrelor is superior to clopidogrel in reducing ischemic events in ACS patients regardless of their diabetes status or glycemic control, without increasing major bleeding risk.
Abstract
ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events.